{"nctId":"NCT00358462","briefTitle":"Mycoplasma Genitalium Antibiotic Susceptibility and Treatment (MEGA)","startDateStruct":{"date":"2007-01"},"conditions":["Urethritis"],"count":606,"armGroups":[{"label":"Active azithromycin+placebo doxycycline","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Azithromycin"]},{"label":"Active doxycycline+placebo azithromycin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Doxycycline"]}],"interventions":[{"name":"Azithromycin","otherNames":["Zithromax","Zmax"]},{"name":"Doxycycline","otherNames":["Doryx","Doxychel","Monodox","Oracea","Periostat","Vibra-Tabs","Vibramycin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Has a visible urethral discharge or greater than or equal to 5 polymorphonuclear leukocytes (PMNs) per high power field on a Gram-stained slide of a urethral swab sample\n* Possesses and is willing to disclose valid contact information for follow-up\n* English-speaking\n* Gives informed consent\n* Exhibits understanding of study procedures\n* Exhibits ability to comply with study procedures for the entire length of the study\n\nExclusion Criteria:\n\n* Has previously participated in this study\n* Has taken antibiotics within the prior month\n* Has known allergies to tetracyclines or azithromycin\n* Is being treated with any of the following: warfarin, ergot derivatives, pimozide (Orap), propafenone (Rytmonorm, Rythmol), disopyramide (Norpace, Rythmodan), rifampin, digoxin, isotretinoin, or methotrexate\n* Has received a kidney, heart, or lung transplant.\n* Is undertaking concomitant systemic steroid therapy","healthyVolunteers":false,"sex":"MALE","minimumAge":"16 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"mITT Analysis of Eradication of M. Genitalium at First Follow-up Study Visit","description":"Microbiologic cure of M. genitalium at first follow-up visit (defined as a negative in-house PCR test performed on urine)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"PRIMARY","title":"mITT Analysis of Eradication of U. Urealyticum at First Follow-up Visit","description":"Microbiologic cure, defined as negative PCR for U. urealyticum (if cultured), or negative culture at first follow-up visit","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Cure Among Case Subjects Who Were Positive for M. Genitalium at the Initial Study Visit","description":"Proportion of men with M. genitalium at the initial study visit who had clinical cure, defined as \\<5 PMNs/HPF (with or without urethral symptoms) on a urethral Gram stain and absence of urethral discharge at follow-up.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Cure Among Case Subjects Who Were Positive for Ureaplasmas at the Initial Study Visit","description":"Proportion of men with Ureaplasma urealyticum at the initial study visit who had clinical cure, defined as \\<5 PMNs/HPF (with or without urethral symptoms) on a urethral Gram stain and absence of urethral discharge at follow-up.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]}]},{"type":"SECONDARY","title":"Minimum Inhibitory Concentrations (MIC) of M. Genitalium for Azithromycin","description":"In vitro susceptibiities of M. genitalium to azithromycin","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Minimum Inhibitory Concentrations (MIC) of M. Genitalium for Doxycycline","description":"In vitro susceptibilities of M. genitalium to doxycycline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Minimum Inhibitory Concentrations (MIC) of U. Ureaplasma Biovar 2","description":"In vitro susceptibilities of U. urealyticum biovar 2","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":null},{"groupId":"OG001","value":"0.5","spread":null},{"groupId":"OG002","value":"0.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Minimum Inhibitory Concentrations (MIC) of U. Parvum","description":"In vitro susceptibilities of U. parvum","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0.25","spread":null},{"groupId":"OG002","value":"0.25","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":304},"commonTop":["Diarrhea","Nausea","Other","Vomiting","Rash"]}}}